Understanding genetic variations associated with familial breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39390525/
Familial breast cancer has been linked to several genetic diseases and mutations, according to studies. Screening for genetic disorders is recommended by National Comprehensive Cancer Network recommendations. Evaluation of breast...
Familial breast cancer involves high- and moderate-penetrance gene mutations, with BRCA1/2 most frequent. Review highlights 20 genes, 10 syndromes, NCCN screening recommendations, and NGS-driven discoveries enhancing risk assessment.
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40204155/
Palbociclib, ribociclib and abemaciclib have different real-world effectiveness in HR-positive/HER2-negative aBC patients. Our findings can support clinicians in choosing the most appropriate CDK4/6i in specific clinical contexts.
This multicenter real-world study compared CDK4/6 inhibitors in HR+/HER2– advanced breast cancer, showing abemaciclib and ribociclib improved progression-free survival versus palbociclib, with differential benefits across patient subgroups.
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39379782/
Outcomes in the Japan subgroup were broadly similar to those of the global population, supporting the clinical benefit of capivasertib-fulvestrant in treating HR-positive/HER2-negative advanced breast cancer that has progressed on,...
Capivasertib-fulvestrant improved progression-free survival in Japanese patients with HR-positive/HER2-negative advanced breast cancer, consistent with global CAPItello-291 results, showing clinical benefit and no new safety concerns.
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39304962/
Breast cancer is the most common malignant tumor among women worldwide and remains one of the leading causes of death among women. Its incidence and mortality rates are continuously rising....
This study reviews deep learning’s role in breast cancer, highlighting improved diagnosis, prognosis, and treatment prediction using models like ResNet50 and Transformers, while stressing data quality, interpretability, and regulatory challenges.
HER2-Low Breast Cancer-Current Knowledge and Future Directions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40282933/
The concept of binary classification of HER2 status has recently been challenged following the DESTINY-Breast trial data showing a clinically meaningful response to antibody-drug conjugates (ADCs) in invasive breast cancer...
HER2-low breast cancer, defined by low IHC scores without gene amplification, shows treatment response to ADCs; review covers definitions, trial data, guidelines, quality considerations, and future directions.